Alpha and Omega Semiconductor Limited ("AOS") (AOSL) today announced that Mr. Yifan Liang, chief financial officer, will present at the 18th Annual B. Riley & Co. Investor Conference on Wednesday, May 24, 2017, at 8:00 a.m. PDT. The conference will take place at Loews Santa Monica Beach Hotel in Santa Monica, California. Mr. Liang will also be available for one-on-one meetings, and interested parties may schedule meetings through their B. Riley representative.
A live and archived webcast of the presentation may be accessed at the Company's website
About Alpha and Omega Semiconductor
Alpha and Omega Semiconductor Limited, or AOS, is a designer, developer and global supplier of a broad range of power semiconductors, including a wide portfolio of Power MOSFET, IGBT and Power IC products. AOS has developed extensive intellectual property and technical knowledge that encompasses the latest advancements in the power semiconductor industry, which enables AOS to introduce innovative products to address the increasingly complex power requirements of advanced electronics. AOS differentiates itself by integrating its Discrete and IC semiconductor process technology, product design, and advanced packaging know-how to develop high performance power management solutions. AOS' portfolio of products targets high-volume applications, including portable computers, flat panel TVs, LED lighting, smart phones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. For more information.
Chicago, IL – May 15, 2017 –Zacks Equity Research Alpha & Omega Semiconductor Limited (NASDAQ: AOSL – Free Report ) as the Bull of the Day, AMAG Pharmaceuticals (NASDAQ: AMAG – Free Report ) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Trade Desk (NASDAQ: TTD – Free Report ).
Here is a synopsis of all three stocks:
Bull of the Day :
Many times management promises a recovery strategy, but then falls short of their expectations. But our Zacks Bull of the Day,Alpha & Omega Semiconductor Limited (NASDAQ: AOSL – Free Report ) was able to increase capacity, improve margins, and crush their recent earnings expectations.
This Zacks Ranked #1 (Strong Buy) is engaged in designing, developing and supplying a broad range of power semiconductors globally, including a portfolio of Power MOSFET and Power IC products. The Company seeks to differentiate itself by integrating its expertise in device physics, process technology, design and advanced packaging to optimize product performance and cost. Its portfolio of products targets high-volume end-market applications, such as notebooks, netbooks, flat panel displays, mobile phone battery packs, set-top boxes, portable media players and power supplies. The Company utilizes third-party foundries for all of its wafer fabrication and it deploys and implements its proprietary MOSFET processes at these third party foundries.
Recent Earnings Results
For Q3 17, AOSL beat the Zacks consensus earnings estimate for the 8th consecutive time, and beat the Zacks consensus revenue estimate for the 6th consecutive time. Further, management increased guidance for the seventh consecutive quarter as well (sales guidance was lifted to $97 million, above the consensus of $96.2 million for Q4 17). On a year over year basis, AOSL saw increases in the following: revenues +12.4%, gross margins improved from +19.7% to +24.3%, operating income was up from -$0.2 million to +$3 million, net income improved from -$1.3 million to +$3.6 million, and income per share rose from $0.06 to $0.14.
According to Dr. Mike Chang, Chairman and CEO, “ Our new product momentum continued to contribute to the revenue and gross margin growth. AOS reported $93.3 million in revenue, close to the high-end of our guidance range, representing an increase of 12.4% from the revenue in the same quarter a year ago. We also posted the eighth consecutive quarter of gradual gross margin expansion and delivered $0.21 non-GAAP earnings per share despite the fact that the March quarter is seasonally our lowest quarter.
"This, once again, demonstrates the strength of AOS recovery strategy that is now translating into a sustained improvement of our financial performance. We are also taking proactive and deliberate steps to gradually alleviate capacity constraints, and we expect to see higher production output starting in the September quarter. The entire team at AOS continues to keenly focus on developing differentiated technologies and introducing market driven new products, which we believe will further propel our business growth and profitability .”
Bear of the Day :
Pharma companies that see fluctuating sales from one of their biggest revenue drivers tend to make investors nervous about their future prospects. Couple this with increasing costs for a new drug with unverified revenue potential, and future earnings estimates begin to fall. These are some of the issues facing our Zacks Bear of the Day:AMAG Pharmaceuticals (NASDAQ: AMAG – Free Report ).
This Zacks Rank #5 (Strong Sell) is a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for women’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.
Recent Earnings Data
On May 2nd, AMAG reported Q1 17 results, and they were not good; the company significantly missed both the Zacks consensus earnings estimate (estimate was $0.09, actual -$1.06), and revenue estimate (estimate $154 million, actual $139 million). The main driver behind the revenue miss was due to two separate items; First, a one-time payment of $60 million to Palatin Technologies “related to the bremelanotide licensing transaction”, and second, the drug Makena, as the untreated segment saw no gains and remained at 30% market share. It is believed that many doctors are not completely sold on the drug’s therapeutic benefits.
Further, the company is expected to see higher SG&A expenses due to the addition of commercial reps for their drug Intrarosa, and the company is facing the ever-present threat of the generic drug impact.
According to William Heiden, President and CEO, “ Today we are reaffirming our 2017 annual revenue guidance on our existing commercial portfolio of Makena, Feraheme and CBR based on the strong underlying fundamentals of those products. "While our commercial team drove higher physician-level Makena demand (distributor shipments to end users) in the first quarter of 2017 compared to the fourth quarter of 2016, first quarter 2017 ex-factory sales of Makena (shipments to distributors) decreased compared to the fourth quarter of 2016. The difference between demand and ex-factory sales was primarily due to a decline in channel inventory, as well as one-time items impacting net price in the first quarter of 2017 .”